Thursday, June 17, 2021

PCCS shine out in FYE 2020 despite challenges from Covid19 pandemic

For latest information, can join us at




As you had know, I had been invested into PCCS earlier this year because of several reasons.

I would summarized the reason I am invested into PCCS, or you can refer to my previous posting on PCCS as a research and referencing material for you to study in depth into PCCS.

My core pointers will be

1. PCCS is diversifying into MEDICAL HEALTHCARE TECHNOLOGY. The joint venture between PCCS and SHANGHAI SHENQI MEDICAL had been finalized, and grounds work are going on in bringing the product into the Asia Pacific market (Excluding China and Japan). The product mainly focus on heart related illness.

2. PCCS had been a accidental beneficiaries with the military coup in Myanmar, where apparel orders will divert to neighboring country. PCCS operation in Cambodia will benefit.

3. PCCS label and packing operation will be looking for a good turnaround with more positive development.

4. PCCS had entered into used car financing venture that will see consistent cashflow for the group.


PCCS had delivered Q4 2020 result in a fantastic manner despite being in the Covid19 pandemic.




PCCS deliver EPS 2.81 cents. Future revenue contributor will be used car financing and sales of medical technology product.



Technical outlook



On the technical outlook, PCCS can be seen trading at the bottom support line of the trading range. At the price range of RM 0.46, the share price is well supported.

RM 0.60 will be the resistant line. Breaking above RM 0.60 will signal a very positive uptrend to the share price.




IMPORTANT NOTICE
Please be informed, I am not a professional or certified analyst. I am not a licensed consultant, just a normal retail investor. I am just sharing my ideas and opinion on the market outlook. Any company mentioned should not be interpreted as a buy/sell/trade call. Please do your own research and buy/sell/trade at your own risk.




For latest information, can join us at

No comments:

Post a Comment